MBQ Pharma

Last updated: 18.07.2019

company_picture

MBQ Pharma anti-metastatic cancer therapies block and prevent metastasis and tumor growth by targeting and inhibiting the Rac/Cdc42 GTPases. Our lead candidate, MBQ-167, is currently the most efficient Rac1 and Cdc42 inhibitor available for research, showing non-clinical efficacy evidence in triple negative breast cancer, HER2 positive trastuzumab-resistant breast cancer, and stomach cancer. We are currently conducting further preclinical studies of MBQ-167 towards Investigational New Drug FDA submission.

 

Contact

MBQ Pharma, Inc.
PO Box 19616,
San Juan, PR 00910

mbqpharma.com

Interviews

Related

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here